Literature DB >> 6401452

Development and operation of a pharmacy-based intravenous cytotoxic reconstitution service.

M Anderson, D Brassington, J Bolger.   

Abstract

An intravenous cytotoxic reconstitution service has proved extremely popular with both medical and nursing staff. Since the pharmacy has taken over the responsibility for presenting these medicines in a readily usable form, many potential hazards to inexperienced medical staff have been eliminated, and much time and money have been saved. The pharmacists are in an excellent position to offer advice on many aspects of excellent position to offer advice on many aspects of cytotoxic treatment and are well equipped to spot prescription errors. They are often asked to supply information concerning rates and methods of administration as well as compatibility data of different diluents with various cytotoxic agents. The eventual objective of the service is to provide reconstituted cytotoxic drugs for all patients in the pharmaceutical district receiving chemotherapy. As it is not practical to have pharmacists available 24 hours a day, some form of batch production of syringe-loaded drugs could be used. In the immediate future the practicality of storing syringe-loaded drugs in a deep freeze (at -20 degrees C) with rapid thawing will be considered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401452      PMCID: PMC1546658          DOI: 10.1136/bmj.286.6358.32

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  16 in total

1.  Acute leukemia as a delayed consequence of cancer chemotherapy.

Authors:  F Rosner
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

2.  Stability of injectable medications after reconstitution.

Authors:  B E Kirschenbaum; C J Latiolas
Journal:  Am J Hosp Pharm       Date:  1976-08

Review 3.  Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature.

Authors:  F Rosner; H Grünwald
Journal:  Am J Med       Date:  1974-12       Impact factor: 4.965

4.  Chemical stability of cyclophosphamide in parenteral solutions.

Authors:  D Brooke; R J Bequette; R E Davis
Journal:  Am J Hosp Pharm       Date:  1973-02

5.  Mutagenicity in urine of nurses handling cytostatic drugs.

Authors:  K Falck; P Gröhn; M Sorsa; H Vainio; E Heinonen; L R Holsti
Journal:  Lancet       Date:  1979-06-09       Impact factor: 79.321

6.  Toxicity of antineoplastic agents in man, chromosomal aberrations antifertility effects, congenital malformations, and carcinogenic potential.

Authors:  S M Sieber; R H Adamson
Journal:  Adv Cancer Res       Date:  1975       Impact factor: 6.242

7.  Acute leukemia after alkylating-agent therapy of ovarian cancer.

Authors:  R R Reimer; R Hoover; J F Fraumeni; R C Young
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

8.  Possible risk of working with antineoplastic drugs in horizontal laminar flow hoods.

Authors:  A L Donner
Journal:  Am J Hosp Pharm       Date:  1978-08

Review 9.  The carcinogenicity of anticancer drugs: a hazard in man.

Authors:  C C Harris
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

10.  Stability of refrigerated and frozen solutions of doxorubicin hydrochloride.

Authors:  D M Hoffman; D D Grossano; L Damin; T M Woodcock
Journal:  Am J Hosp Pharm       Date:  1979-11
View more
  3 in total

Review 1.  Biological safety cabinetry.

Authors:  R H Kruse; W H Puckett; J H Richardson
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

Review 2.  The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

3.  The economics of a pharmacy-based central intravenous additive service for paediatric patients.

Authors:  D J Armour; C J Cairns; I Costello; S J Riley; E G Davies
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.